Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plasma Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,961 result(s) found for: Plasma Cell. Displaying page 1 of 99.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-016607-33 Sponsor Protocol Number: AOL09-DrROYER Start Date*: 2010-01-19
    Sponsor Name:CHU Amiens
    Full Title: Traitement des leucémies primitives à plasmocytes du sujets de moins de 70 ans
    Medical condition: leucémie à plasmocytes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024318 Leukaemia plasmacytic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004170-26 Sponsor Protocol Number: APHP190205 Start Date*: 2021-04-08
    Sponsor Name:Assistance-Publique - Hôpitaux de Paris
    Full Title: PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION PCL-2 Study
    Medical condition: PRIMARY PLASMA CELL LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002557-38 Sponsor Protocol Number: Allo-MM-PostCy-Study Start Date*: 2018-02-13
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054086 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003105-33 Sponsor Protocol Number: EMN12/HO129 Start Date*: 2017-08-02
    Sponsor Name:HOVON
    Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients
    Medical condition: Primary plasma cell leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005638-56 Sponsor Protocol Number: 0805603 Start Date*: 2009-02-16
    Sponsor Name:CHU de TOULOUSE
    Full Title: Protocole IFM 2008 : Primo-traitement des patients de moins de 65 ans atteints de myélome
    Medical condition: Myelome, Myelome multiple
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028566 Myeloma LLT
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001292-11 Sponsor Protocol Number: NMSG 17/07 Start Date*: 2007-08-05
    Sponsor Name:Nordic Myeloma Study Group
    Full Title: Talidomid vs Velcade vid melfalanrefraktärt myelom
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004282-31 Sponsor Protocol Number: V14-11056 Start Date*: 2017-03-15
    Sponsor Name:Vivolux AB
    Full Title: VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001013-89 Sponsor Protocol Number: DAMTE Start Date*: 2018-08-28
    Sponsor Name:AZIENDA OSPEDALIERA "BIANCHI-MELACRINO-MORELLI"
    Full Title: Double ASCT in MM: phase III study comparing between melphalan based regimen vs a new regimen consisting of melphalan and thiotepa
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028566 Myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005563-10 Sponsor Protocol Number: TLI-001-2007 Start Date*: 2007-11-30
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
    Medical condition: Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028228 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000987-31 Sponsor Protocol Number: 35RC17_8825_IMMUNO-MYELO Start Date*: 2021-04-23
    Sponsor Name:CHU Rennes
    Full Title: Immunomonitoring and multiple myeloma: impact of lenalidomide on immune checkpoint expression
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003891-39 Sponsor Protocol Number: HOVON 76 MM Start Date*: 2007-05-22
    Sponsor Name:HOVON Foundation
    Full Title: Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004928-21 Sponsor Protocol Number: Auto-Allo-TSCTinMM Start Date*: 2008-06-27
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study
    Medical condition: Multiple Myeloma Stage II or III according to Salmon and Durie
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003599-39 Sponsor Protocol Number: AMD3100-3102-DE Start Date*: 2005-12-02
    Sponsor Name:AnorMED Corp.
    Full Title: A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal ...
    Medical condition: Mobilization of stem cells prior to autologous stem cell transplantation in patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004580-19 Sponsor Protocol Number: REVIR Start Date*: 2008-10-14
    Sponsor Name:CHU DE POITIERS
    Full Title: PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID®) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003854-33 Sponsor Protocol Number: 90/2006/U/Sper Start Date*: 2006-09-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A multi-centre, randomised study of Zoledronic Acid versus Observation in Patients with Asymptomatic Myeloma
    Medical condition: Newly diagnosed asymptomatic MM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012583-13 Sponsor Protocol Number: gamma delta Start Date*: 2009-10-22
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Phase II study of interleukin-2 and zoledronic acid as maintenance therapy in patients with multiple myeloma having undergone autograft
    Medical condition: Patients with multiple myeloma having undergone autograft
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005007-34 Sponsor Protocol Number: 2006-0101 Start Date*: 2007-04-10
    Sponsor Name:UMCU
    Full Title: Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantation
    Medical condition: multiple myeloma patients with relapse or progression of their disease after receiving an allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005042-23 Sponsor Protocol Number: 2538/2008 Start Date*: 2008-12-02
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Phase II clinic trial for the reduction of time of hematopoietic stem cell engraftment with sitagliptin in patients with multiple myeloma receiving autologous transplantation
    Medical condition: patients affected by multiple myeloma requiring chemotherapy with high-dose melphalan (100 mg/m2).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005425-30 Sponsor Protocol Number: AURA-6202-011 Start Date*: 2008-04-17
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
    Medical condition: Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004264-39 Sponsor Protocol Number: 26866138-MMY-2060 Start Date*: 2009-01-30
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE® on Myeloma related Bone Disease
    Medical condition: Myeloma related bone disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) AT (Completed) GB (Completed) SE (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA